C28H29N7O
479.6 g/mol
APIDanger
N-Desmethyl Imatinib
CAS404844-02-6
Category
API
Compound Class
Amide
Primary Use
Pharmaceutical Raw Material
N-Desmethyl Imatinib is a metabolite of the kinase inhibitor imatinib, formed via N-demethylation primarily by cytochrome P450 3A4. It is used as a pharmaceutical metabolite standard in analytical and research settings.
pharmaceutical metabolite standardlaboratory reference material for analytical testing
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 404844-02-6
Related Compounds
SimilarStructure SimilarSimilarity 0.85
Imatinib
CAS152459-95-5
pharmaceutical raw material
SimilarStructure SimilarSimilarity 0.85
Imatinib mesylate
CAS220127-57-1
pharmaceutical raw material
SimilarStructure SimilarSimilarity 0.81
N-Desmethyl N-Nitroso Imatinib
CAS2816369-80-7
research compound
SimilarStructure SimilarSimilarity 0.80
4-[(4-Methyl-4-oxo-4λ⁵-piperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
CAS571186-91-9
pharmaceutical raw material
ReferenceSame Category
Besifloxacin hydrochloride
CAS405165-61-9
pharmaceutical raw material
ReferenceSame Category
Mitomycin b
CAS4055-40-7
pharmaceutical raw material
ReferenceSame Category
Carnitine
CAS406-76-8
pharmaceutical raw material
ReferenceSame Category
7β-fulvestrant
CAS407577-53-1
pharmaceutical raw material
Safety Reference
Danger
H341Suspected of causing genetic defects
H351Suspected of causing cancer
H362May cause harm to breast-fed children
Identifiers
IUPAC Name
N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(piperazin-1-ylmethyl)benzamide
InChIKey
BQQYXPHRXIZMDM-UHFFFAOYSA-N
SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCNCC3)NC4=NC=CC(=N4)C5=CN=CC=C5
Synonyms (11)
- Imatinib EP Impurity C
- N-Desmethyl Gleevec
- N-Desmethyl Imatinib
- Norimatinib